CA3221939A1 - Analogues de n-(hydroxyalkyl(hetero)aryl)tetrahydrofurane carboxamide en tant que modulateurs de canaux sodiques - Google Patents

Analogues de n-(hydroxyalkyl(hetero)aryl)tetrahydrofurane carboxamide en tant que modulateurs de canaux sodiques Download PDF

Info

Publication number
CA3221939A1
CA3221939A1 CA3221939A CA3221939A CA3221939A1 CA 3221939 A1 CA3221939 A1 CA 3221939A1 CA 3221939 A CA3221939 A CA 3221939A CA 3221939 A CA3221939 A CA 3221939A CA 3221939 A1 CA3221939 A1 CA 3221939A1
Authority
CA
Canada
Prior art keywords
compound
pain
pharmaceutically acceptable
acceptable salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3221939A
Other languages
English (en)
Inventor
Elizabeth Mary BECK
Dean Stamos
Joanne Louise Pinder
Rebecca E. STEVENS
Mark Thomas Miller
Sarah Skerratt
Gorka ETXEBARRIA JARDI
James Dodd
Lidio Marx Carvalho Meireles
Joseph Pontillo
Steven John Durrant
David Matthew Shaw
Ronald Marcellus KNEGTEL
Yvonne Schmidt
Bhairavi GALAN
Reece JACQUES
Nadia M. Ahmad
Timothy Donald Neubert
Stephen Andrew Thomson
Robert PULLIN
Bruno Artur SOUSA
Christopher Wray
Alexander KINTZER
Sara S. Hadida Ruah
Dennis James Hurley
Michael Edward O'donnell
Kiri NORTH
Ewa Iwona CHUDYK
Anisa Nizarali Virani
Jinglan Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CA3221939A1 publication Critical patent/CA3221939A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

L'invention concerne des composés de formule (I) et des sels pharmaceutiquement acceptables de ceux-ci, utiles en tant qu'inhibiteurs de canaux sodiques. L'invention concerne également des compositions pharmaceutiques comprenant les composés ou des sels pharmaceutiquement acceptables et des procédés d'utilisation des composés, des sels pharmaceutiquement acceptables, et des compositions pharmaceutiques dans le traitement de divers troubles, y compris de la douleur.
CA3221939A 2021-06-04 2022-06-03 Analogues de n-(hydroxyalkyl(hetero)aryl)tetrahydrofurane carboxamide en tant que modulateurs de canaux sodiques Pending CA3221939A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163196970P 2021-06-04 2021-06-04
US63/196,970 2021-06-04
PCT/US2022/032202 WO2022256679A1 (fr) 2021-06-04 2022-06-03 Analogues de n-(hydroxyalkyl(hétéro)aryl)tétrahydrofurane carboxamide en tant que modulateurs de canaux sodiques

Publications (1)

Publication Number Publication Date
CA3221939A1 true CA3221939A1 (fr) 2022-12-08

Family

ID=82358540

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3221939A Pending CA3221939A1 (fr) 2021-06-04 2022-06-03 Analogues de n-(hydroxyalkyl(hetero)aryl)tetrahydrofurane carboxamide en tant que modulateurs de canaux sodiques

Country Status (5)

Country Link
EP (1) EP4347584A1 (fr)
CN (1) CN117794919A (fr)
AU (1) AU2022286438A1 (fr)
CA (1) CA3221939A1 (fr)
WO (1) WO2022256679A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024041613A1 (fr) * 2022-08-24 2024-02-29 江苏恒瑞医药股份有限公司 Composé hétérocyclique, son procédé de préparation et son utilisation pharmaceutique
WO2024046253A1 (fr) * 2022-08-28 2024-03-07 上海汇伦医药股份有限公司 Régulateur de canal sodique et son utilisation
WO2024046409A1 (fr) * 2022-08-31 2024-03-07 江苏恒瑞医药股份有限公司 Composé hétérocyclique, son procédé de préparation et son utilisation pharmaceutique

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
AU2001275881B2 (en) 2000-07-10 2006-04-06 Vertex Pharmaceuticals (San Diego) Llc Ion channel assay methods
CA2672549A1 (fr) 2001-11-14 2003-06-12 Ben-Zion Dolitzky Formes cristallines amorphes de losartan potassique et leur procede de preparation
AP2007003887A0 (en) 2004-07-23 2007-02-28 Pfizer Pyridine derivatives
AU2007319580B2 (en) 2006-10-12 2012-11-29 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
GEP20125379B (en) 2007-05-03 2012-01-10 Pfizer Ltd 2 -pyridine carboxamide derivatives as sodium channel modulators
RU2518073C2 (ru) 2008-12-26 2014-06-10 ДАЙНИППОН СУМИТОМО ФАРМА Ко., ЛТД. Новое бициклическое гетероциклическое соединение
US9174999B2 (en) 2009-05-07 2015-11-03 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for studying, imaging, and treating pain
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011026240A1 (fr) 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Dérivés d'oxopipérazine pour le traitement de la douleur et de l'épilepsie
EP2595989B1 (fr) 2010-05-06 2016-07-13 Vertex Pharmaceuticals Incorporated Amides de chromène hétérocyclique-pipéridine spirocyclique utiles comme modulateurs des canaux ioniques
US8916565B2 (en) 2011-02-02 2014-12-23 Vertex Pharmaceuticals Incorporated Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
US10385070B2 (en) 2011-02-18 2019-08-20 Vertex Pharmaceuticals Incorporated Chroman-spirocyclic piperidine amides as modulators of ion channels
ES2786298T3 (es) 2011-03-03 2020-10-09 Zalicus Pharmaceuticals Ltd Inhibidores de benzimidazol del canal de sodio
US8828996B2 (en) 2011-03-14 2014-09-09 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
CA2850925C (fr) 2011-10-26 2017-01-10 Pfizer Limited Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal de sodium
EP2788332A1 (fr) 2011-12-07 2014-10-15 Amgen, Inc. Inhibiteurs aryle et hétéroaryle bicycliques des canaux calciques
CN104136442B (zh) 2012-01-16 2016-12-21 沃泰克斯药物股份有限公司 作为离子通道调节剂的吡喃‑螺环哌啶酰胺类
JP6002785B2 (ja) 2012-02-03 2016-10-05 ファイザー・インク ナトリウムチャネルモジュレーターとしてのベンゾイミダゾールおよびイミダゾピリジン誘導体
WO2013131018A1 (fr) 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Inhibiteurs biaryle du canal sodique
US9051311B2 (en) 2012-03-09 2015-06-09 Amgen Inc. Sulfamide sodium channel inhibitors
US20140211173A1 (en) 2013-01-30 2014-07-31 3M Innovative Properties Company Optical projection subsystem
CN105026373B (zh) 2013-01-31 2018-03-30 沃泰克斯药物股份有限公司 作为钠通道调节剂的吡啶酮酰胺
WO2014120820A1 (fr) 2013-01-31 2014-08-07 Vertex Pharmaceuticals Incorporated Amides comme modulateurs des canaux sodiques
AU2014212426B8 (en) 2013-01-31 2018-05-10 Vertex Pharmaceuticals Incorporated Quinoline and Quinoxaline Amides as Modulators of Sodium Channels
US9776995B2 (en) 2013-06-12 2017-10-03 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
MX364155B (es) 2013-07-19 2019-04-12 Vertex Pharma Sulfonamidas como moduladores de canales de sodio.
AU2014362255B2 (en) 2013-12-13 2019-08-29 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
CA2944549A1 (fr) 2014-04-09 2015-10-15 Siteone Therapeutics, Inc. Saxitoxines 10',11'-modifiees pour le traitement de la douleur
JP6742331B2 (ja) 2015-03-02 2020-08-19 アムジエン・インコーポレーテツド 二環式ケトンスルホンアミド化合物
EP3356370B1 (fr) 2015-09-30 2021-08-18 Siteone Therapeutics, Inc. Saxitoxines 11,13-modifiées destinées au traitement de la douleur
EP3601290B1 (fr) 2017-03-29 2021-11-24 Siteone Therapeutics, Inc. Saxitoxines 11,13-modifiées destinées au traitement de la douleur
BR112019020111A2 (pt) 2017-03-29 2020-05-05 Siteone Therapeutics Inc saxitoxinas 11,13-modificadas para o tratamento de dor
KR20200006128A (ko) 2017-05-16 2020-01-17 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 중수소화 피리돈 아미드 및 이의 프로드럭
SG11202000230VA (en) 2017-07-11 2020-02-27 Vertex Pharma Carboxamides as modulators of sodium channels
AU2019301628A1 (en) 2018-07-09 2021-01-28 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting NaV1.8
US20210139456A1 (en) 2018-07-09 2021-05-13 Lieber Institute, Inc. Pyridazine compounds for inhibiting nav1.8
WO2020072835A1 (fr) 2018-10-03 2020-04-09 Siteone Therapeutics, Inc. Saxitoxines modifiées 11,13 pour le traitement de la douleur
JP7288051B2 (ja) 2018-11-02 2023-06-06 メルク・シャープ・アンド・ドーム・エルエルシー Ｎａｖ１．８阻害薬としての２－アミノ－Ｎ－ヘテロアリール－ニコチンアミド類
WO2020092187A1 (fr) 2018-11-02 2020-05-07 Merck Sharp & Dohme Corp. 2-amino-n-phényl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
WO2020117626A1 (fr) 2018-12-05 2020-06-11 Merck Sharp & Dohme Corp. Composés d'aryle sulfonamide substitués par 4-amino ou 4-alcoxy ayant une activité sélective dans des canaux sodiques sensibles à la tension
EP3907218A4 (fr) 2019-01-04 2022-09-21 Jiangsu Hengrui Medicine Co., Ltd. Dérivé de 6-oxo-1,6-dihydropyridazine, son procédé de préparation et son utilisation médicale
US20230062053A1 (en) 2019-01-10 2023-03-02 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US20220110923A1 (en) 2019-01-10 2022-04-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020151728A1 (fr) 2019-01-25 2020-07-30 江苏恒瑞医药股份有限公司 Derive de 2-oxo-1,2-dihydropyridine, son procede de preparation et ses applications medicales
MA56398A (fr) 2019-06-27 2022-05-04 Glaxosmithkline Ip Dev Ltd Composés 2,3-dihydroquinazoline en tant qu'inhibiteurs de nav1.8
CN112300069A (zh) 2019-07-31 2021-02-02 明慧医药（上海）有限公司 一种选择性钠通道调节剂及其制备和应用
CN112300051A (zh) 2019-07-31 2021-02-02 明慧医药（上海）有限公司 一种选择性钠通道调节剂及其制备和应用
TW202115038A (zh) 2019-08-19 2021-04-16 大陸商江蘇恆瑞醫藥股份有限公司 苯甲醯胺稠芳環類衍生物、其製備方法及其在醫藥上的應用
CN112390745B (zh) 2019-08-19 2022-10-21 江苏恒瑞医药股份有限公司 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用
CN112441969A (zh) 2019-08-30 2021-03-05 明慧医药（上海）有限公司 一种选择性钠通道调节剂及其制备和应用
WO2021047622A1 (fr) 2019-09-12 2021-03-18 上海济煜医药科技有限公司 Oxynitrure de pyridine, son procédé de préparation et son utilisation
KR20220124176A (ko) 2019-12-06 2022-09-13 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 치환된 테트라하이드로푸란
CN111217776A (zh) 2020-01-19 2020-06-02 中国人民解放军军事科学院军事医学研究院 含苯并杂环结构的酰胺衍生物、组合物和应用
JP2021195368A (ja) 2020-06-10 2021-12-27 アムジエン・インコーポレーテツド シクロブチルジヒドロキノリンスルホンアミド化合物
AU2021288190A1 (en) 2020-06-10 2022-12-22 Amgen Inc. Heteroalkyl dihydroquinoline sulfonamide compounds
JP2021195367A (ja) 2020-06-10 2021-12-27 アムジエン・インコーポレーテツド シクロプロピルジヒドロキノリンスルホンアミド化合物
CA3182633A1 (fr) 2020-06-17 2021-12-23 Ashok Arasappan 2-oxoimidazolidine-4-carboxamides utilises en tant qu'inhibiteurs de nav1.8
MX2022015579A (es) 2020-06-17 2023-01-24 Merck Sharp & Dohme Llc 2-oxo-oxazolidin-5-carboxamidas como inhibidores de nav1.8.
JP2023530320A (ja) 2020-06-17 2023-07-14 メルク・シャープ・アンド・ドーム・エルエルシー Ｎａｖ１．８阻害剤としての５－オキソピロリジン－３－カルボキサミド
BR112023002659A2 (pt) 2020-08-14 2023-05-02 Siteone Therapeutics Inc Inibidores de cetona não hidratados de nav1.7 para o tratamento da dor
TW202214259A (zh) 2020-08-19 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 一種選擇性ＮａＶ抑制劑的前藥及其晶型
WO2022037647A1 (fr) 2020-08-19 2022-02-24 江苏恒瑞医药股份有限公司 Forme cristalline d'inhibiteur sélectif de nav et son procédé de préparation
CN111808019B (zh) 2020-09-08 2020-11-27 上海济煜医药科技有限公司 一种并环化合物及其应用
CN112225695B (zh) 2020-12-15 2021-03-02 上海济煜医药科技有限公司 一种氮氧化合物及其制备方法和用途
CN112457294B (zh) 2021-01-27 2021-06-04 上海济煜医药科技有限公司 一种作为NaV1.8阻滞剂的化合物及其制备方法和用途

Also Published As

Publication number Publication date
EP4347584A1 (fr) 2024-04-10
WO2022256679A1 (fr) 2022-12-08
CN117794919A (zh) 2024-03-29
AU2022286438A1 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
US11919887B2 (en) Substituted tetrahydrofurans as modulators of sodium channels
AU2014362255B2 (en) Prodrugs of pyridone amides useful as modulators of sodium channels
WO2020146612A1 (fr) Esters et carbamates utilisés en tant que modulateurs de canaux sodiques
US20230062053A1 (en) Carboxamides as modulators of sodium channels
CA3221939A1 (fr) Analogues de n-(hydroxyalkyl(hetero)aryl)tetrahydrofurane carboxamide en tant que modulateurs de canaux sodiques
US11827627B2 (en) N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
WO2022256702A1 (fr) Tétrahydrofuran-2-carboxamides substitués utiles en tant que modulateurs de canaux sodiques
CA3221960A1 (fr) Tetrahydrofuranes a substitution hydroxy et (halo)alkoxy utiles en tant que modulateurs de canaux sodiques
WO2022256676A1 (fr) Analogues de tétrahydrofurane substitués utiles en tant que modulateurs de canaux sodiques
OA21241A (en) Substituted tetrahydrofurans as modulators of sodium channels.
NZ710293B2 (en) Amides as modulators of sodium channels